<DOC>
	<DOCNO>NCT01853306</DOCNO>
	<brief_summary>This 3 part phase 1 study evaluate safety , pharmacokinetic oral bioavailability veliparib subject solid tumor .</brief_summary>
	<brief_title>A Study Evaluate Safety , Pharmacokinetics Oral Bio Availability Veliparib Subjects With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<criteria>1 . Part 1 2 : Histologically cytologically confirm malignancy metastatic unresectable standard curative measure therapy may provide clinical benefit exist longer effective . Subjects must also 1 ) document BRCA1 BRCA2 mutation consider deleterious investigator , OR 2 ) high grade serous ovarian , fallopian tube , peritoneal cancer . Subjects molecular feature indicative DNA repair defect ( mutation Fanconi anemia pathway gene methylation BRCA1 promoter ) may consider eligible follow discussion medical monitor . Part 3 : Histologically cytologically confirm breast , ovarian , fallopian tube primary peritoneal cancer metastatic unresectable standard curative measure therapy may provide clinical benefit exist longer effective . Platinumresistant ovarian cancer permit . Subjects must also 1 ) document BRCA1 BRCA2 mutation consider deleterious investigator 2 ) receive 3 few regimen cytotoxic chemotherapy metastatic set 3 ) evaluable disease define RECIST 1.1 GCICCA125 criterion . 2 . Subject must least 18 year age . 3 . Completion last anticancer therapy must least 28 day prior study drug administration . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance score 0 2 . 5 . Subject must adequate hematologic , renal hepatic function follow : Bone Marrow : Absolute neutrophil count ANC ≥ 1,500/mm3 ( 1.5 × 109/L ) ; Platelets ≥ 100,000/mm3 ( 100 × 109/L ) ; Hemoglobin ≥ 9.5 g/dL ( 1.4 mmol/L ) . Subjects hemoglobin ≥ 9.5 g/dL ( 1.4 mmol/L ) follow transfusion eligible ; Renal function : A calculated creatinine clearance value ≥ 50 mL/min determine Cockcroft Gault formula creatinine clearance value ≥ 50 mL/min base 24hour urine collection ; Hepatic function : AST ALT ≤ 2.5 × upper normal limit institution 's normal range . For subject liver metastasis , AST ALT ≤ 5 × upper normal limit institution 's normal range ; Bilirubin : → 1.5 × upper normal limit institution 's normal range . 6 . Women childbearing potential men must agree use adequate contraception prior study entry , duration study participation 3 month follow completion therapy . Women childbearing potential must negative pregnancy test within 7 day prior initiation treatment and/or post menopausal woman must amenorrheic least 12 month consider nonchildbearing potential . total abstinence sexual intercourse preferred life style subject ; periodic abstinence acceptable ; vasectomize partner ( ) ; hormonal contraceptive ( oral , parenteral transdermal ) least 3 month prior study drug administration ; intrauterine device ( IUD ) ; Male subject ( include vasectomize ) whose partner pregnant might pregnant must agree use condom duration study 90 day follow completion therapy . 7 . Subject must capable understand comply parameter outline protocol able sign inform consent , approve Institutional Review Board ( IRB ) prior initiation screen study specific procedure . 8 . Must voluntarily sign date inform consent , approve Independent Ethics Committee ( IEC ) /Institutional Review Board ( IRB ) , prior initiation screen studyspecific procedure . 1 . The subject must receive antitumor radiotherapy , biologic therapy , chemotherapy , immunotherapy within 28 day 5 half life ( whichever short ) start Day 1 . The subject must receive hormonal therapy antitumor purpose within 1 week prior start Cycle 1 Day 1 . 2 . Subject must know untreated brain meningeal metastasis . CT scan require rule brain meningeal metastases unless clinical suspicion central nervous system disease . Subjects treat brain metastasis radiographically clinically stable least 4 week therapy evidence cavitation hemorrhage brain lesion ( ) eligible , provide asymptomatic require corticosteroid ( must discontinue steroid least one week prior study drug administration ) . 3 . Clinically significant uncontrolled major medical condition ( ) include limited : Uncontrolled nausea/vomiting/diarrhea ; Active uncontrolled infection ; Symptomatic congestive heart failure ; Unstable angina pectoris cardiac arrhythmia ; Psychiatric illness/social situation would limit compliance study requirement ; Focal generalize seizure within last 12 month . 4 . Any medical condition , opinion study investigator , place subject unacceptably high risk toxicity ; 5 . Subject receive strong inhibitor inducer CYP3A , 1A1 , 2D6 , 2C19 within 3 day five halflives ( whichever short ) prior first dose veliparib ( applicable Part 1 ) . 6 . Subject pregnant lactating . 7 . Subjects previously treat veliparib . 8 . For Part 3 , subject ovarian cancer previously treat platinum base chemotherapy result progression free survival &lt; 6 month completion treatment . 9 . For Part 3 , subject receive 4 prior line cytotoxic chemotherapy systemic disease . 10 . Subject require parenteral nutrition , tube feed evidence partial bowel obstruction perforation within 28 day prior study drug administration . 11 . The subject another active malignancy within past 3 year except cancer situ Principal Investigator considers cure . Questions regard inclusion individual subject direct Medical Monitor . 12 . History gastric surgery , vagotomy , bowel resection surgical procedure might interfere gastrointestinal motility , pH absorption . 13 . Receipt investigational product within 28 day prior study drug administration 5 halflives , whichever longer . 14 . Current enrollment another clinical study . 15 . Consideration investigator , reason , subject unsuitable candidate receive veliparib .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>High grade serous ovarian cancer</keyword>
	<keyword>BRCA mutate breast cancer</keyword>
	<keyword>BRCA mutate</keyword>
	<keyword>Oncology</keyword>
</DOC>